Soliman, Hatem
Wagner, Susanne
Flake, Darl D. II
Robson, Mark
Schwartzberg, Lee
Sharma, Priyanka
Magliocco, Anthony
Kronenwett, Ralf
Lancaster, Johnathan M.
Lanchbury, Jerry S.
Gutin, Alexander
Gradishar, William
Funding for this research was provided by:
Myriad Genetics, Inc.
Article History
Received: 10 May 2019
First Online: 6 January 2020
Disclosure
: This study was financially supported by Myriad Genetics, Inc. SW, DF, RK, JML, JSL, and AG were all employed by Myriad Genetics at the time of the study. DF has a patent for a similar technology (PCT/US2015/027091 filed April 22, 2015). MR has served as an advisor for and received travel/accommodation expenses from AstraZeneca; has received institutional research funding from AbbVie, AstraZeneca, Invitae, Medivation, Myriad Genetics, Inc., Pfizer, and Tesaro; has received in-kind research funding from Invitae and Myriad Genetics, Inc.; has received other transfers of value (editorial services) from Pfizer; and his research on this project was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. LS has financial activities with Amgen, GSK, Spectrum, Medivation, Bayer, Genentech, Pfizer, Sanofi, BMS, Novartis, and MedImmune outside of the submitted work. PS has served on an advisory board for Myriad Genetics, Inc. All other authors report no conflicts of interest. This study has previously been presented at ASCO 2018.